Chávez-López EL, Alemán-Ortiz OF, Nando-Villicaña CC, Rosas-Munive E

Idioma: Español
Referencias bibliográficas: 157
Paginas: 39-52
Archivo PDF: 239.37 Kb.

RESUMEN

La disfunción cardiaca y la renal coexisten con alta prevalencia. Se ha definido a esta entidad clínica como síndrome cardiorrenal y una de sus características principales es la resistencia al tratamiento. Se han descrito múltiples hipótesis para explicar su fisiopatología, como la desregulación hemodinámica y, recientemente, mecanismos neurohumorales e inmunológicos que intervienen en su desarrollo y perpetuación. Se clasifica de acuerdo con su forma de presentación y componentes fisiopatológicos. Existen distintos enfoques terapéuticos para controlar o limitar el progreso de la enfermedad. Esta revisión discute y analiza la información actual sobre la fisiopatología, la clasificación y el tratamiento de esta entidad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Nhibi.nih.gov [homepage on the internet]. Cardio-renal connections in heart failure and cardiovascular disease. National Heart, Lung and Blood Institute. [Updated 2005 February 18; cited 2014 Oct 10] Available from: http://www.nhlbi.nih.gov/research/reports/2004-cardiorenal-hf-hd.

2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52: 1527-1539.

3. Bock JS, Gottlieb SS. Cardiorenal syndrome new perspectives. Circulation. 2010; 121: 2592-2600.

4. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol. 2012; 9: 99-111.

5. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012; 125: e2.

6. Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149: 209-216.

7. Fonarow GC, Adams KF jr, Abraham WT et al. Risk stratification for in hospital mortality in acutely descompensated heart failure classification and regression tree analysis. JAMA. 2005; 293: 572-580.

8. Roger VL et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011; 123: 180-209.

9. Konstam MA. Systolic and diastolic dysfunction in heart failure? Time for a new paradigm. J Card Fail. 2003; 9: 1-3.

10. Cleland JGF, Khand A, Clark A. The heart failure epidemic: exactly how big is it?. Eur Heart J. 2001; 22: 623-626.

11. McMurray JJ, Stewart S. Heart failure. Epidemiology, etiology, and prognosis of heart failure. Heart. 2000; 83: 596-602.

12. Zile MR, Brutsaert DL. New concepts in diastolic function and diastolic heart failure: part I y II. Diagnosis, prognosis and measurements of diastolic function. Circulation. 2002; 105: 1387-1393.

13. Ojeda S, Anguita M, Muñoz JF, Rodríguez MT, Mesa D, Franco M et al. Características clínicas y pronóstico a medio plazo de la insuficiencia cardiaca con función sistólica conservada. ¿Es diferente de la insuficiencia cardiaca sistólica?. Rev Esp Cardiol. 2003; 56: 1050-1056.

14. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. Prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999; 33: 1948-1955.

15. Campos-Nonato I, Hernández-Barrera L, Rojas-Martínez R, Pedroza-Tobías A, Medina-García C, Barquera S. Hipertensión arterial: prevalencia, diagnóstico oportuno, control y tendencias en adultos mexicanos. Salud Publica Mex. 2013; 55 (Supl 2): S144-S150.

16. Orea TA, Férez SS, Ortega SA. Programa Nacional de Registro de Insuficiencia Cardiaca. Resultados de un estudio multicéntrico mexicano. Med Int Mex. 2004; 20: 243-260.

17. Rubinger D. Management of refractory congestive heart failure-a nephrological challenge. Nephrol Dial Transplant. 2005; (Suppl 7): 37-40.

18. Arora N, Dellsperger K. Heart failure and dialysis: new thoughts and trends. Advanc Periton Dial. 2007; 23: 72-75.

19. Silverberg D, Wexler K, Blum M et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004; 13: 163-170.

20. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382: 339-352.

21. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012; 379: 165-180.

22. Allon M. Evidence-based cardiology in hemodialysis patients. J Am Soc Nephrol. 2013; 24: 1934-1943.

23. El Nahas M. Cardio-kidney-damage: a unifying concept. Kidney Int. 2010; 78: 14-18.

24. Cheung AK, Sarnak MJ, Yan G, Berkoben M et al. HEMO Study Group: cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004; 65: 2380-2389.

25. Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol. 2012; 23: 1929-1939.

26. Tonelli M, Muntner P, Lloyd A. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012; 380: 807-814.

27. Obrador GT, Villa AR, Olvera N et al. Longitudinal analysis of participants in the KEEP Mexico’s chronic kidney disease screening program. Arch Med Res. 2013; 44: 650-654.

28. Gutiérrez-Padilla JA, Mendoza-García M, Plascencia-Pérez S et al. Screening for CKD and cardiovascular disease risk factors using mobile clinics in Jalisco, Mexico. Am J Kidney Dis. 2010; 55: 474-484.

29. Heywood JT, Elatre W, Pal RC et al. Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther. 2005; 10: 173-180.

30. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcome in heart failure. J Am Coll Cardiol. 2006; 47: 1987-1996.

31. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu Y. Chronic kidney disease and the risk of death, cardiovascular events and hospitalization. N Engl J Med. 2004; 351: 1296-1305.

32. Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol. 1993; 3: 1878-1883.

33. Chen ZM, Pan HC, Chen YP et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366: 1622-1632.

34. Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care. 2004; 10: 476-482.

35. Ronco C. NGAL: an emerging biomarker of acute kidney injury. Int J Artif Organs. 2008; 31: 199-200.

36. Wagener G, Jan M, Kim M et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology. 2006; 105: 485-491.

37. Parikh CR, Jani A, Mishra J et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006; 6: 1639-1645.

38. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40: 221-226.

39. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the Intensive Care Unit. J Am Soc Nephrol. 2005; 16: 3046-3052.

40. Fu P, Arcasoy MO. Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochem Biophys Res Commun. 2007; 354: 372-378.

41. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci. 2008; 29: 258-267.

42. Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007; 154: 645.

43. Blake P, Hasegawa Y, Khosla MC, Fouad-Tarazi F, Sakura N, Paganini EP. Isolation of “myocardial depressant factor(s)” from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J. 1996; 42: M911.

44. Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007; 357: 1316-1325.

45. Figueras J, Stein L, Diez V, Weil MH, Shubin H. Relationship between pulmonary hemodynamics and arterial pH and carbon dioxide tension in critically ill patients. Chest. 1976; 70: 466-472.

46. Brady JP, Hasbargen JA. A review of the effects of correction ofacidosis on nutrition in dialysis patients. Semin Dial. 2000; 13: 252-255.

47. McCullough PA, Sandberg KR. Chronic kidney disease and sudden death: strategies for prevention. Blood Purif. 2004; 22: 136-142.

48. Gandhi SK, Powers JC, Nomeir AM et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001; 344: 17-22.

49. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol. 2006; 47: e1-e192.

50. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007; 49: 1079-1088.

51. Liang F, O’Rear J, Schellenberger U et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007; 49: 1071-1078.

52. Spanaus KS, Kronenberg F, Ritz E et al. B-type natriuretic peptide concentrations predict the progression of non diabetic chronic kidney disease: the mild-to-moderate kidney disease study. Clin Chem. 2007; 53: 1264-1272.

53. Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm. 2008; 2008: 135625.

54. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358: 2148-2159.

55. Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care. 2002; 8: 376-388.

56. Chen D, Assad-Kottner C, Orrego C, Torre-Amione G. Cytokines and acute heart failure. Crit Care Med. 2008; 36: S9-S16.

57. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003; 14: 1549-1558.

58. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-S266.

59. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1-12.

60. Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002; 137: 563-570.

61. Beattie JN, Soman SS, Sandberg KR et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis. 2001 37: 1191-1200.

62. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003; 42: 201-208.

63. French WJ, Wright RS. Renal insufficiency and worsened prognosis with STEMI: a call for action. J Am Coll Cardiol. 2003; 42: 1544-1546.

64. Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008; 36 (1 Suppl.): S75-S88.

65. Hillege HL et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113: 671-678.

66. Blake WD, Wegria R, Keating RP, Ward HP. Effect of increased renal venous pressure on renal function. Am J Physiol. 1949; 157: 1-13.

67. Malbrain ML, Cheatham ML, Kirkpatrick, Sugrue M, Parr M, De Waele J et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. Intensive Care Med. 2006; 32: 1722-1732.

68. Bradley SE, Bradley GP. The effect of increased intra-abdominal pressure on renal function in man. J Clin Invest. 1947; 26: 1010-1015.

69. Meldrum DR, Moore FA, Moore EE, Franciose RJ, Sauaia A, Burch JM. Prospective characterization and selective management of the abdominal compartment syndrome. Am J Surg. 1997; 45: 667-673.

70. Maeder MT, Holst DP, Kaye DM. Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J Card Fail. 2008; 14: 824-830.

71. Mullens W et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009; 53: 589-596.

72. Bristow MR. Treatment of chronic heart failure with b-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2001; 109: 1176-1194.

73. Bristow MR et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in non failing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986; 59: 297-309.

74. Bristow MR et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993; 92: 2737-2745.

75. Jaisser F, Swynghedauw B, Delcayre C. The mineralocorticoid receptor in heart: different effects in different cells. Hypertension. 2011; 57: 679-680.

76. Lother A et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2004; 57: 746-754.

77. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983; 1: 1385-1390.

78. Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail. 2008; 10: 176-187.

79. Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006; 86: 901-940.

80. Funaya H et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation. 1997; 95: 1363-1365.

81. Griendling KK, Minieri CA, Ollerensaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994; 74: 1141-1148.

82. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003; 63: 179-185.

83. Heymes C et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003; 41: 2164-2171.

84. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009; 4: 1384-1387.

85. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003; 100: 4802-4806.

86. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res. 1991; 69: 1088-1096.

87. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension. 1991; 17: 187-193.

88. Cook P, Rossitch E, Andon NA, Loscalzo L, Dazu VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest. 1991; 88: 1663-1671.

89. Ferrari R, Bachetti T, Agnoletti L, Comini L, Curello S. Endothelial function and dysfunction in heart failure. Eur Heart J. 1998; 19 (Suppl. G): G41-G47.

90. Giannattasio C, Piperno A, Failla M, Vergani A, Mancia G. Effects of hematocrit changes on flow-mediated and metabolic vasodilation in humans. Hypertension. 2002; 40: 74-77.

91. Francis GS. TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing. Circulation. 1999; 99: 3213-3214.

92. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323: 236-241.

93. Stenvinkel P, Ketteler M, Johnson LJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005; 67: 1216-1233.

94. Karalliedde J, Viberti G. Proteinuria in diabetes: by stander or pathway to cardiorenal disease?. J Am Soc Nephrol. 2010; 21: 2020-2027.

95. Kasory A, Ross E. Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol. 2009; 53: 639-647.

96. Tang WH, Tong W, Jain A et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008; 51: 569-576.

97. Mendes-Ribeiro AC, Brunini TM, Ellory JC, Mann GE. Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc Res. 2001; 49: 697-712.

98. Sandgren PE et al. Anemia and new-onset congestive heart failure in the general Medicare population. J Card Fail. 2005; 11: 99-105.

99. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002; 85: 51-66.

100. Kalantar-Zadeh K et al. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next?. Semin Dial. 2005; 18: 365-369.

101. Sukhanov S et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci. 2011; 342: 143-147.

102. Pilz S et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008; 93: 3927-3935.

103. Zittermann A et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol. 2003; 41: 105-112.

104. Lind L, Wengle B, Ljunghall S. Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study. Acta Med Scand. 1987; 222: 423-427.

105. Jüppner H. Phosphate and FGF-23. Kidney Int. 2011; 79: S24-S27.

106. Faul C et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121: 4393-4408.

107. London GM et al. Mineral metabolism and arterial functions in endstage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18: 613-620.

108. Plischke M et al. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest. 2012; 42: 649-656.

109. Kovesdy CP, Darryl-Quarles L. Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol Dial Transplant. 2013; 28: 2228-2236.

110. Zoppellaro G, Faggin E, Puato M et al. Fibroblast growth factor 23 and the bone-vascular axis: lessons learned from animal studies. Am J Kidney Dis. 2012; 59: 135-144.

111. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Intern. 2012; 82: 737-747.

112. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000; 35: 681-689.

113. Shlipak MG et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol. 2009; 20: 2625-2630.

114. USRDS; the United States Renal Data System. USRDS 2003 annual data report. Am J Kidney Dis. 2003; 421-230.

115. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal followup and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Inter Med. 2004; 164: 659-663.

116. Mebazaa A, Gheorghiade M, Pina IL et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008; 36: S129-S139.

117. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care. 2004; 8: R204-R212.

118. Schaffer AC. Urianalysis and urine electrolytes. In: Lawry GV, McKean SC, Matloff J, Ross JJ, Dressler DD, Brotman DJ eds. Principles and practice of hospital medicine. New York, USA: MacGraw-Hill; 2012: p. 10.

119. Cruz DN, Fard A, Clementi A, Ronco C, Maisel A. Role of biomarkers in the diagnosis and management of cardio-renal syndromes. In Sem Nephrol. 2012; 32 (1): 79-92.

120. Freda BJ, Tang WW, van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency review and clinical implications. J Am Col Cardiol. 2002; 40: 2065-2071.

121. Kreder KJ, Williams RD. Urologic laboratory examination. In: Tanagho EA, McAninch JW eds. Smith’s general urology. 17th ed. New York: McGraw-Hill; 2008.

122. Fauchauld P. Effects of ultrafiltration of body fluid and transcapillary colloid osmotic gradient in hemodialysis patients, improvements in dialysis therapy. Contrib Nephrol. 1989; 74: 170-175.

123. Shchekochikhin D, Lindenfeld J, Schrier RW. Increased spironolactone in advanced HF: effect of doses greater than 25 mg/day on plasma potassium concentration. Cardiorenal Med. 2013; 3: 1-6.

124. Francis GS, Siegel RM, Goldsmith SR. Acute vasoconstrictior response to intravenous furosemide in patients with chronic congestive HF. Activation of the nuerohumoral axis. Ann Intern Med. 1985; 103: 1-6.

125. Silverstein ME, Ford CA, Lysaght MJ, Henderson LW. Treatment of severe fluid overload by ultrafiltration. N Engl J Med. 1974; 291: 747-751.

126. Lucas C, Johnson W, Hamilton MA et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000; 140: 840-847.

127. Metra M, Cleland JG, Weatherley BD et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. Eur J Heart Fail. 2010; 12: 499-507.

128. Metra M, Teerlink JR, Felker GM et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail. 2010; 12: 1130-1139.

129. Binanay C, Califf RM, Hasselblad V et al. ESCAPE investigators and ESCAPE study coordinators: evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005; 294: 1625-1633.

130. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43: 61-67.

131. Hasselblad V, Gattis-Stough W, Shah M. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007; 9: 1064-1069.

132. Mielniczuk LM, Tsang SW, Desai AS. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008; 14: 388-393.

133. Kazory A. Cardiorenal syndrome: ultrafiltration therapy for heart failure-trials and tribulations. Clin J Am Soc Nephrol. 2013; 8: 1816-1828.

134. Guazzi MD, Agostoni P, Perego B et al: Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J. 1994; 72: 534-539.

135. Marenzi G, Lauri G, Grazi M et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001; 38: 963-968.

136. Agostoni P, MarenziG, Lauri G et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: Failure of furosemide to provide the same result. Am J Med. 1994; 96: 191-199.

137. Giglioli C, Landi D, Cecchi E et al. Effects of ultrafiltration versus diuretics on clinical, biohumoral and haemodynamic variables in patients with decompensated heart failure: the ULTRADISC study. Eur J Heart Fail. 2011; 13: 337-346.

138. Damman K, van Deursen VM, Navis G et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009; 53: 582-588.

139. Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol. 1931; 72: 49-61.

140. Bart BA, Goldsmith SR, Lee KL et al. Ultrafiltration in decompensated HF with CRS. N Engl J Med. 2012; 367: 2296-2304.

141. Rosario LB, Stevenson LW, Solomon SD et al. The mechanism of decrease in dynamic mitral regurgitation during HF treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol. 1998; 32: 1819-1824.

142. Stevenson LW, Brunken RC, Belil D et al. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced HF. J Am Coll Cardiol. 1990; 15 (1): 174-180.

143. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005; 142: 510-524.

144. Parissis JT, Rafouli-Stergiou P, Stasinos V et al. Inotropes in cardiac patients: update 2011. Curr Opin Crit Care. 2010; 16: 432.

145. Follath F, Yilmaz MB, Delgado JF et al. Clinical presentation, management and outcomes in the acute HF global survey of standard treatment (ALARM-HF). Intensive Care Med. 2011; 37: 619-626.

146. Elkayam U, Tasissa G, Binanay C et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe HF. Am Heart J. 2007; 153: 98-104.

147. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of Dopamine and dobutamine in patients with cardiomyopathic HF. Circulation. 1978; 58: 466-475.

148. Valika AA, Gheorghiade M. Ace inhibitor therapy for HF in patients with impaired renal function: a review of the literature. Heart Fail Rev. 2012; 18: 135-140.

149. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive HF during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992; 70: 479-487.

150. Oster JR, Meterson BJ. Renal and electrolyte complications of congestive HF and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med. 1992; 152: 704-710.

151. Packer M. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic HF. Ann Intern Med. 1987; 106: 346-354.

152. Con J, Joseph B, Kulvatunyou N, Tang A, O’Keeffe T, Wynne JL et al. Evidence-based immune-modulating nutritional therapy in critically ill and injured patients. Eur Surg. 2011; 43: 13-18.

153. Buijsse B, Feskens EJ, Schlettwein-Gsell D, Ferry M, Kok FJ, Kromhout D et al. Plasma carotene and α-tocopherol in relation to 10-y all-cause and cause-specific mortality in European elderly: the survey in Europe on nutrition and the elderly, a concerted action (SENECA). Am J Clin Nutr. 2005; 82: 879-886.

154. Mangoni AA. Folic acid, inflammation, and atherosclerosis: false hopes or the need for better trials?. Clin Chimica Acta. 2006; 367: 11-19.

155. Singleton KD, Wischmeyer PE. Glutamine attenuates inflammation and NF-kB activation via Cullin-1 deneddylation. Biochem Biophys Res Commun. 2008; 373: 445-449.

156. Enos RT, Davis JM, Velázquez KT, McClellan JL, Day SD, Carnevale KA et al. Influence of dietary saturated fat content on adiposity, macrophage behavior, inflammation, and metabolism: composition matters. J Lipid Res. 2013; 54: 152-163.

157. Wong MCY, Emery PW, Preedy VR, Wiseman H. Health benefits of isoflavones in functional foods? Proteomic and metabonomic advances. Inflammopharmacology. 2008; 16: 235-239.